Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Inherited metabolic brain disorders produce changes in brain metabolism and structure as a result of genetic mutations. Clinically, children with metabolic brain disorders often present with nonspecific symptoms, such as hypotonia, seizures, and developmental delay, which often makes diagnosis difficult. A combination of neurologic symptoms with and without visceral manifestation and age at onset of symptoms often are important factors indicating an underlying inherited metabolic brain disorder. The diagnosis traditionally has been accomplished by laboratory analyses of biologic specimens (urine or blood) and tissue (muscle or fibroblast) biopsy. However, the increased availability of imaging studies incorporating advanced techniques, specifically magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI) and MR spectroscopy (MRS), offers more diagnostic features, thereby improving the ability to recognize disease patterns and classify patients for metabolic and genetic investigations with candidate diseases prioritized from imaging and clinical features. Although the number of metabolic brain disorders is significant, neuroradiologists should be able to recognize the features of the key disorders outlined in this chapter.
Because these disorders generally are progressive, the classification of neurodegenerative features also is used appropriately as imaging findings worsen—for example, cortical volume loss, gliosis, and hypomyelination. The generic term “hypomyelination” is used to describe abnormal myelination, whether it is improperly formed or altered after formation, because distinguishing demyelination from dysmyelination is a pathologic diagnosis not distinguished objectively by imaging alone. Because these diseases frequently or primarily involve the white matter, they often are put into a general category of leukodystrophy. The known leukodystrophies are genetic diseases involving defects in oligodendroglia function and myelinogenesis. The term “leukodystrophy” describes a chronic, progressive, destructive process of the white matter within the central nervous system (CNS) characterized by a metabolic disorder of myelin sheath formation and maintenance, often with a slow but progressive loss of nervous system structures. The clinical course is progressive and typically includes mental retardation with signs of long tract dysfunction, such as pyramidal and cerebellar disturbances, with abnormal conduction of visual auditory and somatic sensory input as measured by evoked potentials.
In young children, more heavily T2-weighted sequences with a repetition time of 2,500 to 3,000 msec and time to echo (TE) of 100 to 200 msec should be obtained. It is difficult to evaluate the degree of myelination in children younger than 2 years because the normal myelination process does not begin until the fifth month of fetal gestation and proceeds rapidly during the first 2 years of life. Fluid-attenuated inversion recovery (FLAIR) imaging may be misleading before 18 months of age because it sharpens the difference between myelinated and even physiologically unmyelinated white matter. By 2 years of age, 90% of all the white matter fiber tracts have become myelinated, but myelination is incomplete, and some variability exists in the meeting of various milestones. In children younger than 2 years, destructive processes may not be adequately demonstrated on T2-weighted images. However, by 2 years of age and older, destructive processes resulting in white matter fiber abnormal T2 hyperintensity is demonstrated in the leukodystrophies. In recent reports, contrast enhancement has been helpful because many of the newly recognized leukodystrophies have disruption of the blood-brain barrier. The end-stage appearance of all the leukodystrophies on computed tomography (CT) or MRI is marked generalized volume loss. Most leukodystrophies involve the central white matter in a symmetric fashion; Canavan disease is the exception. Patients with delayed myelination or symmetrically abnormal myelination from an earlier insult may have an imaging appearance similar to an early leukodystrophy, making radiologic diagnosis less accurate. Symptoms in these children may be similar to those in children with a leukodystrophy.
DWI provides information about the gross mobility of water (see also Chapter 26 ). Cytotoxic and myelinic edema can produce a hyperintense signal of diffusion-weighted images. To distinguish this signal from a hyperintense signal arising from T2 weighting, an apparent diffusion coefficient (ADC) map can be generated. On an ADC map, cytotoxic and myelinic edema generates a hypointense signal, indicating a restriction of water diffusion. Diffusion tensor imaging holds the promise of providing white matter microstructural details by revealing the magnitude and direction of water movement along the axons. As myelination is detected, water molecules demonstrate reduced diffusivity and increased diffusion anisotropy. Abnormal myelin can be quantitated from changes in these properties using measures such as mean diffusivity and fractional anisotropy.
MRS is useful in the evaluation of metabolic diseases in children because many laboratory studies that test for systemic metabolic diseases often do not reveal abnormalities, especially when the metabolic derangements are within localized regions of the brain. When CNS involvement is demonstrated on anatomic MR images, the MRS spectrum is usually abnormal. In some metabolic disorders, abnormalities are observed in the MRS spectrum in the absence of anatomic MR abnormalities (e.g., creatine deficiency syndromes).
In the evaluation of a possible metabolic disorder, acquiring both short- and long-echo spectra offers the most diagnostic utility. The use of a short echo time allows for the detection of metabolites with faster T2 decay, especially glutamine/glutamate and myo-inositol (mI). The long-echo spectra have a flatter baseline, which is important for the detection of lactate, a double resonance at 1.3 ppm. Identification of lactate within cerebral tissue typically reflects mitochondrial impairment and should raise suspicion of mitochondrial disease, with confirmation by a muscle biopsy and possibly laboratory analyses of serum or cerebrospinal fluid (CSF). Mitochondrial enzyme systems are involved in many key cell metabolic pathways—oxidative phosphorylation, oxidation of fatty acids and amino acids, and processes involved in the Krebs cycle and part of the urea cycle. Abnormal lactate accumulation detected in patients with mitochondrial disorders can reflect the following mechanisms: (1) a high degree of nonoxidative glycolysis resulting from impaired oxidative energy metabolism, (2) the use of anaerobic metabolism by infiltrating macrophages, and (3) damage to or loss of viable neuroaxonal tissue.
This chapter includes as a reference a large listing of metabolic brain diseases encountered in imaging ( Tables 33.1 to 33.10 ). For convenience, the recognized metabolic or genetic defect and the patterns of inheritance are summarized. However, because of space limitations, the following discussion will address only the most commonly encountered of these rare disorders.
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Neonatal adrenoleukodystrophy | PTS1 and Peroxin genes | 202370 | Autosomal recessive | Peroxisomal | Deficiency in oxidizing VLCFA |
X-linked adrenoleukodystrophy | Adrenoleukodystrophy; ALD/ABCD1 (Xq28) | 300100 | X-linked | Peroxisomal | Inability to oxidize VLCFA into shorter chain fatty acids |
Alexander disease | Glial fibrillary acidic protein; GFAP (17q21.31) | 203450 | Autosomal dominant | Leukodystrophy | Presence of Rosenthal fibers, glial fibrillary acid proteins in astrocytes |
Alpers disease | Nuclear encoded mitochondrial DNA polymerase-gamma; POLG (15q26.1) | 203700 | Autosomal recessive | Mitochondrial | Respiratory chain abnormalities |
Argininemia (arginase deficiency) | Arginase; ARG1 (6q23.2) | 207800 | Autosomal recessive | Urea cycle | Defect encoding enzyme ARG1 |
Argininosuccinate lyase deficiency | Argininosuccinate lyase; ASL (7q11.21) | 207900 | Autosomal recessive | Urea cycle | Defect encoding enzyme ASL |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Biotinidase deficiency | Biotinidase gene; BTD (3p25.1) | 253260 | Autosomal recessive | Organic or amino acid | Biotinidase deficiency with elevated lactate, β-hydroxyisovalerate |
Canavan disease | Aspartoacylase; ASPA (17p13.2) | 271900 | Autosomal recessive | Leukodystrophy | Enzyme deficiency; aspartoacylase deficiency; inability to metabolize NAA into aspartate and acetate |
Carbamoyl phosphate synthetase I deficiency | Carbamoyl phosphate synthetase I; CPS1 (2q34) | 237300 | Autosomal recessive | Urea cycle | Defect encoding enzyme; CPS1 enzyme deficiency; catalyzes first committed step in the urea cycle |
Cerebrotendinous xanthomatosis | 27-sterol hydroxylase: CYP27 (2q35) | 213700 | Autosomal recessive | Lysosomal | Enzyme deficiency—sterol 27-hydroxylase |
Childhood ataxia with diffuse CNS hypomyelination (vanishing white matter) | EIF2B1-5 (12q24.31, 14q24.3, 1p34.1, 2p23.3, 3q27) | 603896 | Autosomal recessive | Leukodystrophy | Gene defect in eukaryotic translation initiation factor (mRNA translated into proteins) |
Citrullinemia, classic (argininosuccinate synthetase deficiency) | Argininosuccinate synthetase; ASS (9q34.11) | 215700 | Autosomal recessive | Urea cycle | Gene defect encoding enzyme argininosuccinate synthetase |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Cockayne disease | Excision-repair cross-complementing group 8 gene; ERCC8 (5q12.1) | 216400 | Autosomal recessive | Miscellaneous | Defective DNA repair |
Congenital muscular dystrophies | Fukuyama: fukutin; FCMD (9q31.2) | 253800 | Autosomal recessive | Congenital muscular dystrophy | Defect in dystrophin-associated proteins |
Merosin-deficient: laminin alpha-2-gene; LAMA2 (6q22.33) | 607855 | Autosomal recessive | Congenital muscular dystrophy | Absence of merosin in muscle | |
Duchenne: dystrophin DMD (Xp21.2–p21.1) | 310200 | X-linked recessive | Congenital muscular dystrophy | Absence of dystrophin in muscle | |
Creatine deficiency—creatine transporter defect | SLC6A8 (Xq28) | 300352 | X-linked | Miscellaneous | Creatine transport impaired to the brain |
Creatine deficiency—arginine:glycine amidinotransferase deficiency | GATM (15q21.1) | 612718 | Autosomal recessive | Miscellaneous | Creatine synthesis impaired |
Creatine deficiency—guanidinoacetate methyltransferase deficiency | GAMT (19p13.3) | 612736 | Autosomal recessive | Miscellaneous | Creatine synthesis impaired |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Ethylmalonic aciduria | ETHE1 (19q13.31) | 602473 | Autosomal recessive | Organic or amino acid | Ethylmalonic aciduria with cytochrome c oxidase deficiency in skeletal muscle; lactic acidemia |
Galactosemia | galactose-1-phophate uridylyltransferase; GALT (9p13.3) | 230400 | Autosomal recessive | Miscellaneous | Defect encoding galactose-1-phosphate uridyltransferase |
Globoid cell leukodystrophy (Krabbe disease) | Galactocerebrosidase; GALC (14q31.3) | 245200 | Autosomal recessive | Lysosomal | Enzyme deficiency—galactocerebroside beta-galactosidase deficiency |
Glutaric aciduria | Type I glutaryl-CoA-dehydrogenase; GCDH (19p13.13) | 231670 | Autosomal recessive | Organic or amino acid | Enzyme deficiency altering metabolism of lysine, hydroxylysine, tryptophan |
Glutaric aciduria | Type II multiple acyl CoA-dehydrogenase genes (19q13.41, 15q24.2–q24.3, 4q32.1) | 231680 | Autosomal recessive | Organic or amino acid | Disorder of fatty acid, amino acid, and choline metabolism |
Homocystinuria | Cystathionine β-synthase; CBS (21q22.3) | 236200 | Autosomal recessive | Organic or amino acid | Increased urinary homocystine and methionine |
L-Hydroxyglutaric aciduria | L2HGDH 14q21.3 | 236792 | Autosomal recessive | Organic or amino acid | Increase of L-2-hydroxy glutaric acid in urine |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Isovaleric acidemia | Isovaleryl CoA dehydrogenase; IVD (15q15.1) | 243500 | Autosomal recessive | Organic or amino acid | Accumulation of isovaleric acid |
Juvenile Huntington disease | Huntington; HTT (4p16.3) | 143100 | Autosomal dominant | Miscellaneous | Neural cell death from production of quinolinic acid |
Kearns-Sayre syndrome | Various mitochondrial deletions | 530000 | Mitochondrial | Mitochondrial | Lactic acidosis, decreased Co-Q |
Kernicterus | Uridine diphosphate-glucuronosyltransferase; UGT1A1 (2q37.1) | 237900 | Autosomal recessive | Miscellaneous | Hyperbilirubinemia |
b-Ketothiolase deficiency | Acetyl-Co-A-acetyltransferase 1; ACAT1 (11q22.3) | 203750 | Autosomal recessive | Organic or amino acid | Increased urinary 2-methyl-3-hydroxybutyric acid |
Leigh syndrome | Nuclear and mitochondrial-encoded genes involved in energy metabolism | 256000 | Autosomal recessive, mitochondrial | Mitochondrial | Lactic acidosis |
Leukoencephalopathy with brainstem and spinal cord involvement with elevated lactate | DARS2 (1q25.1), mitochondrial aspartyl-tRNA synthetase | 611105 | Autosomal recessive | Leukodystrophy | Lactic acidosis |
Lowe disease | Phosphatidylinositol polyphosphate 5-phosphatase; OCRL (Xq26.1) | 309000 | X-linked recessive | Organic or amino acid | Increased phosphatidylinositol-4,5-biphosphate |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Maple syrup urine disease | Mutations in the catalytic subunit genes of the branched chain alpha ketoacid dehydrogenase complex; BCKD, DBT, DLD (19q13.2, 6q14.1, 1p21.2) | 248600 | Autosomal recessive | Organic or amino acid | Defect in the genes of the branched chain alpha ketoacid dehydrogenase blocking oxidative decarboxylation |
MELAS | Multiple mitochondrial genes | 540000 | Mitochondrial | Mitochondrial | Lactic acidosis |
Menkes disease | Cu(2+) transporting ATPase, alpha polypeptide; ATP7A (Xq21.1) | 309400 | X-linked recessive | Mitochondrial | Low copper |
Metachromatic leukodystrophy | Arylsulfatase A; ASA/ARSA (22q13.33) | 250100 | Autosomal recessive | Lysosomal | Decreased arylsulfatase A, ARSA activity |
Methylmalonic aciduria | Methylmalonyl-CoA mutase; MUT (6p12.3) | 251000 | Autosomal recessive | Organic or amino acid | Defect in methylmalonyl-CoA mutase; disorder of methylmalonate and cobalamin metabolism |
Molybdenum cofactor deficiency | Molybdenum cofactors; MOCS1 (6p21.3); MOCS2 (5q11.2); gephyrin GPHN (14q23.3) | 252150 | Autosomal recessive | Miscellaneous | Increased urinary sulfite, taurine, and xanthine |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
MPS IH—Hurler | alpha-L-iduronidase; IDUA (4p16.3) | 607014 | Autosomal recessive | Lysosomal | α-L-Iduronidase deficiency |
MPS II—Hunter | duronate 2-sulfatase; IDS (Xq28) | 309900 | X-linked recessive | Lysosomal | Iduronate sulfatase deficiency |
MPS III—San Fillipo | N-sulfoglucosamine sulfonhydrolase; SGSH (17q25.3) | 252900 | Autosomal recessive | Lysosomal | Heparan sulfate deficiency |
N-alpha-acetylglucosaminidase; NAGLU (17q21.2) | 252920 | Autosomal recessive | Lysosomal | N-Acetyl-α-D-glucosaminidase, α-Glucosamine-N-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase | |
MPS IV—Morquio | galactosamine-6-sulfate sulfatase; GALNS (16q24.3) | 253000 | Autosomal recessive | Lysosomal | N-Acetylgalactosamine-6-sulfate sulfatase, B galactosidase |
MPS IS—Scheie | IDUA (4p16.3) | 607016 | Autosomal recessive | Lysosomal | α-L-Iduronidase |
MPS VI—Maroteaux-Lamy | arylsulfatase; ARSB (5q14.1) | 253200 | Autosomal recessive | Lysosomal | Arylsulfatase B |
MPS VII—Sly | beta-glucuronidase; GUSB (7q11.21) | 253220 | Autosomal recessive | Lysosomal | β-Glucuronidase |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Neuronal ceroid lipofuscinosis | CLN3 (16p11.2) | 204200 | Autosomal recessive | Lysosomal | Defects involve lysosomal function |
Niemann-Pick type C | NPC1 (18q11.2) | 257220 | Autosomal recessive | Lysosomal | Defective cholesterol esterification due to a deficiency of sphingomyelinase |
Nonketotic hyperglycinemia | Multiple genes ( GLDC [9p24.1], GCSH [16q23.2], AMT [3p21.31]) | 605899 | Autosomal recessive | Amino aciduria | Defective mitochondrial enzyme involved in glycine cleavage |
Ornithine transcarbamylase deficiency | Ornithine carbamoyltransferase; OTC (Xp11.4) | 311250 | X-linked recessive | Urea cycle | Gene defect encoding enzyme ornithine carbamoyltransferase |
Pantothenate kinase (Hallervorden-Spatz) | Pantothenate kinase; PANK (20p13) | 234200 | Autosomal recessive | Mitochondrial | Iron deposition in globus pallidus, caudate, and substantia nigra |
Pelizaeus-Merzbacher | Proteolipid protein; PLP1 (Xq22.2) | 312080 | X-linked | Leukodystrophy | Duplication or deficiency of PLP gene results in altered myelin |
Phenylketonuria | Phenylalanine hydroxylase (12q23.2) | 261600 | Autosomal recessive | Amino aciduria | Phenylalanine hydroxylase deficiency |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Propionic aciduria | Propionic-CoA carboxylase; PCCB (3q22.3) and PCCA (13q32.3) | 232050 | Autosomal recessive | Organic or amino acid | Defect in propionic-CoA carboxylase |
Pyruvate decarboxylase deficiency | E1-alpha polypeptide of pyruvate dehydrogenase; PDHA1 (Xp22.12) | 312170 | X-linked | Mitochondrial | Defect in first of 3 enzymes in PDH-glycolysis and TCA cycle |
Pyruvate dehydrogenase deficiency | Multiple genes of the pyruvate dehydrogenase complex | Multiple | Multiple | Mitochondrial | Defect in enzymes coupling glycolysis and TCA cycle for conversion of pyruvate to acetyl-CoA |
Refsum disease | Infant: PEX1 7q21.2, PXMP3 8q21.11, PEX26 22q11.21 Adult: PHYH 10p13, PEX7 6q23 | 266510, 266500 | Autosomal recessive | Peroxisomal | Phytanic acid oxidase deficiency |
Ribose 5-phosphate isomerase deficiency | Ribose 5-phosphate isomerase deficiency; RPIA 2p11.2 | 608611 | Autosomal recessive | Leukodystrophy | Deficiency in ribose 5-phosphate isomerase |
Salla disease | SLC17A5 (6q13) | 604369 | Autosomal recessive | Lysosomal | Defect in sialic acid transport at the lysosomal membrane |
Sandhoff disease | Hexosaminidase; HEXB 5q13.3 | 268800 | Autosomal recessive | Lysosomal | Defect in beta subunit of hexosaminidase A and B isoenzymes |
Disorder | Gene Name; Abbreviation (Locus) | OMIM | Mode of Inheritance | Primary Classification | Primary Defect |
---|---|---|---|---|---|
Sjögren-Larsson syndrome | Fatty aldehyde dehydrogenase; ALDH3A2 (17p11.2) (17p11.2) | 270200 | Autosomal recessive | Lysosomal | Fatty alcohol oxidation failure |
Succinate semialdehyde dehydrogenase deficiency | Succinic semialdehyde dehydrogenase; ALDH5A1 (6p22.3) | 271980 | Autosomal recessive | Organic or amino acid | Succinic semialdehyde dehydrogenase deficiency with 4-hydroxybutyricaciduria |
Tay-Sachs disease | Hexosaminidase A; HEXA 15q23 | 272800 | Autosomal recessive | Lysosomal | Defect in alpha subunit of hexosaminidase A |
Vacuolating megalencephalic leukoencephalopathy (with subcortical cysts, MLC) | MLC1 (22q13.33) | 604004 | Autosomal recessive | Leukodystrophy | Defect in MLC1 |
Walker-Warburg syndrome | protein O-mannosyltransferase-1; POMT1 (9q34.13) | 236670 | Autosomal recessive | Congenital muscular dystrophy | Elevated creatine kinase; defective glycosylation of alpha-dystroglycan |
Wilson disease | ATP7B (13q14.3) | 277900 | Autosomal recessive | Miscellaneous | Defect in copper transport |
Zellweger syndrome | Several genes involved in peroxisome biogenesis, PEX1 (7q21.2) | 214100 | Autosomal-recessive | Peroxisomal | Decreased dihydroxyacetone phosphate acyltransferase (DHAP-AT) activity |
Many neurodegenerative diseases are characterized by the accumulation of nondegradable molecules in cells or at extracellular sites in the brain. Lysosomes are intracellular organelles responsible for degrading lipids, proteins, and complex carbohydrates. In most lysosomal disorders, the genetic mutation resulting in the absence or deficiency of an enzyme or protein is known and functionally understood. In most, the substrate for the defective enzyme builds up, leading to intralysosomal storage. Although the diseases are complex, storage of nondegradable material primarily leads to neuronal dysfunction rather than neuronal loss. Exceptions are the differential loss of Purkinje cells that characterize several storage diseases (including Niemann-Pick disease type C) and the massive cell loss that occurs in the neuronal ceroid lipofuscinoses (NCLs). It is not known whether the storage material affects cellular function only when it begins to accumulate in extralysosomal sites or if problems in cell homeostasis are triggered while the material is still confined to the lysosome.
Lysosomal disorders typically are inherited as autosomal-recessive traits, usually afflict infants and young children, and are untreatable. The collective frequency of lysosomal storage diseases is estimated to be approximately 1 in 8,000 live births, with some occurring at higher frequency in select populations.
Lysosomal disorders primarily affecting gray matter include the gangliosidoses, mucopolysaccharidoses, and NCLs. Two of the more common lysosomal disorders, metachromatic leukodystrophy (MLD) and Krabbe disease, demonstrate abnormalities in white matter. However, broader involvement of gray and white matter often occurs in later stages of lysosomal disease progression.
The gangliosidoses are divided into two groups, referred to as GM1 and GM2. In the GM1 group, the primary enzyme deficiency is in β-galactosidase, and in the GM2 group there is a hexosaminidase deficiency.
Three types of GM1 gangliosidosis exist: type I (infantile), type II (late infantile/juvenile), and type III (adult). An intermediate form between infantile and juvenile has been reported. The clinical presentation of GM1 gangliosidosis typically occurs in infancy; its features include seizures, decerebrate posturing, pitting edema of the face, hypotonia, developmental delay, hepatosplenomegaly, macrocephaly, and cherry-red spots involving the macula of the retina. Additional features include broad digits, kyphoscoliosis, skeletal dysplasia with widening of the metaphyses, and dermal pigmentary lesions. The course is progressive, with death common by 2 years of age. The juvenile form presents during the second year of life with progressive ataxia, but without many features of the infantile variety.
The underlying deficiency of β-galactosidase results in accumulation of GM1 ganglioside in both gray and white matter of the cerebrum, brainstem, cerebellum, and spinal cord. Results of cerebral MRI initially are normal, with subsequent loss of cortical gray matter. Secondary changes to the white matter manifest later and typically exhibit an abnormal, nonspecific, patchy, hyperintense T2 signal within the centrum semiovale. Hypointensity of the thalami on T2-weighted images also has been reported.
The most common forms of GM2 gangliosidoses include Tay-Sachs disease and Sandhoff disease. Tay-Sachs disease arises with β- N -acetylhexosaminidase-A isoenzyme deficiency in Jewish children of eastern European descent. Onset is usually before the age of 1 year with irritability, hypotonia, seizures, blindness, and cherry-red spots on the macula in 90% of patients. Death usually results by 2 to 3 years of age. Sandhoff disease is attributed to a deficiency of A and B isoenzymes of hexosaminidase. The clinical course is similar to that of Tay-Sachs disease. There is visceral involvement, including hepatomegaly and cardiac and renal tubular abnormalities. Brain MRI in the early stages demonstrates increased T2 signal in the basal ganglia, particularly with enlarged caudate nuclei. Later, cortical and deep gray matter volume loss occurs with patchy increases in T2 signal in the white matter. Thalamic involvement is more reflective of Sandhoff disease. In adult-onset Sandhoff disease, lower motor neuron involvement has been reported. Cerebellar atrophy is variable and does not correlate with clinical severity. In persons with Tay-Sachs disease, the thalami may be hypointense on T2-weighted images and hyperintense on T1-weighted images because of calcium deposition. T2-weighted hyperintensity in cerebral matter may indicate abnormal myelin production and active demyelination. Elevated levels of cytokines have been reported, possibly indicating inflammation as a contributing factor to the progression of gangliosidosis. In the B1 variant of GM2 gangliosidosis, the thalami may appear hyperdense/hyperintense on CT and T1-weighted MRI and show T2-hypointense signal in the ventral thalami and a hyperintense signal in the posteromedial thalami. Other findings in this variant include involvement of the medullary lamellae, bilateral T2 hyperintense/swollen basal ganglia, diffuse white matter hyperintensity on T2-weighted images, and brain atrophy in later stages.
The mucopolysaccharidoses are the best known of the lysosomal abnormalities affecting predominately gray matter. The primary metabolic defect is a failure to break down sulfates (dermatan, heparan, and keratan); mucopolysaccharides fill and overburden the lysosomes within histiocytes of the brain, bone, skin, and other organs. Glycosaminoglycans accumulate with target organs such as the bone, liver, and brain. Eight subtypes have been defined; however, six distinct forms are now recognized within this classification scheme, based on which metabolite is involved. The six are referred to as Hurler (IH), Hunter (II), Sanfilippo (III), Morquio (IV), Maroteaux-Lamy (VI), and Sly (VII), with the classic prototypical disease being Hurler syndrome. All of these diseases are autosomal recessive except Hunter (type II), which is an X-linked recessive condition. Coarse facial features and complex skeletal manifestations are well-known clinical characteristics for all of these disorders. Without treatment, death usually comes within the first decade of life.
MRI demonstrates two major abnormalities ( Fig. 33.1 ): (1) diffuse patches of hyperintensity on T2-weighted images resulting from accumulation of mucopolysaccharide in neurons and astrocytes and degenerative effects on myelin, and (2) prominent cystic or perivascular spaces resulting from metabolite accumulation within histiocytes located in perivascular areas, which is the most characteristic imaging feature; reversal of these changes after bone marrow transplantation has been reported. Hydrocephalus is common, probably as a result of plugging of the pacchionian granulations. Spinal stenosis is especially common in Morquio and Maroteaux-Lamy variants but may be demonstrated in other variants. Bullet-shaped vertebral bodies are characteristic.
For the mucopolysaccharidoses, proton MRS reveals a broad resonance at 3.7 ppm, which is attributed to a composite of mucopolysaccharide molecules. After bone marrow transplantation, the resonance at 3.7 ppm decreases in the brain of some patients, which may aid in determining the efficacy of the therapy. N-acetylaspartate (NAA) levels may improve in response to treatment.
NCL is a group of disorders characterized by striking volume loss of brain parenchyma. NCL, which can be divided into six subtypes based on age at onset, is one of the most common neurodegenerative syndromes, with an incidence of 1 per 25,000 live births. The various subtypes are associated with different mutations in the CLN genes and have similar clinical manifestations occurring at different ages. These manifestations include seizures and abnormal eye movements with subsequent vision loss, dementia, hypotonia, and speech and motor deficits. CSF neurotransmitter abnormalities have been reported. At pathology, these disorders are characterized by distinctive granular inclusions in neuronal lysosomes (granular osmiophilic deposits). Imaging findings lag the clinical presentation in all but the infantile form of NCL and are dominated by progressive cerebral and cerebellar volume loss. Later disease stages are characterized by the development of a band of hyperintense signal in the periventricular white matter on T2-weighted images. In palmitoyl protein thioesterase-1 related NCL, isolated, symmetric dentate nucleus T2 hyperintensities have been reported in early stages. Proton MRS has shown progressive decreases in NAA and relative increases in mI in persons with NCL.
The primary metabolic defect in MLD is a deficiency in the enzyme arylsulfatase A, resulting in lysosomal accumulation of cerebroside sulfate. MLD has four subtypes: congenital, late infantile, juvenile, and adult. The late infantile subtype is the most common and presents from around 14 months to 4 years of age. The early presentations are an unsteady gait that progresses to severe ataxia and flaccid paralysis, dysarthria, mental retardation, and decerebrate posturing. Gallbladder involvement has been reported, possibly appearing before the onset of neurologic symptoms. Intestinal involvement also has been reported, specifically polypoid masses in one patient.
Histologic analysis of the abnormal nervous tissue demonstrates a complete loss of myelin (demyelination) followed by axonal degeneration. Metachromatic granules are reported within engorged lysosomes in white matter and neurons, and on peripheral nerve biopsies. Oligodendrocytes are reduced in number, and areas of demyelination predominate throughout the deep white matter region. An inflammatory response typically is absent, which accounts for a lack of enhancement, but eventually even myelinated white matter is replaced by astrogliosis and scarring. The corpus callosum is involved early, whereas subcortical arcuate white matter fibers (“U” fibers) remains unaffected until the disease has progressed; atrophy is a late sign. Demyelination also can be seen in the posterior limbs of the internal capsule, descending pyramidal tracts, and the cerebellar white matter. Thalamic changes may be common in primary MLD, and isolated cerebellar atrophy may be seen in some atypical later-onset variants. On T2-weighted images, there is marked hyperintensity of the white matter fiber tracts involving the cerebral hemispheres that may extend to the cerebellum, brainstem, and spinal cord. The findings initially are focal and patchy, but later, a diffuse, hyperintense T2 signal of the centrum semiovale develops. Two distinct white matter appearances have been noted that mimic what was previously considered to be pathognomonic of Pelizaeus-Merzbacher disease (PMD) and globoid cell leukodystrophy (Krabbe disease). Punctate areas of hypointensity (“leopard skin” appearance) and radiating patterns of linear tubular structures of T2 hypointensity (“tigroid” appearance) are seen, with areas of relatively normal-appearing white matter within the areas of demyelination. On T1-weighted images, the white matter fibers may be isointense with, or hypointense to, gray matter ( Fig. 33.2 ).
Proton MRS studies have demonstrated reduced NAA, which is expected with neuroaxonal loss, but they also have revealed disturbances in glial cell metabolism associated with elevated mI and choline. The levels of NAA in white matter have been found to correlate with motor function in children with MLD.
Globoid cell leukodystrophy (Krabbe disease) arises from a deficiency in the enzyme β-galactocerebrosidase, leading to the accumulation of cerebroside and galactosylsphingosine, which induces apoptosis in oligodendrocyte cell lines. It is an autosomal-recessive disorder with a frequency of 2 in 100,000. Onset of symptoms usually begins between 3 and 5 months after birth with irritability. Disease progression leads to symptoms mimicking encephalitis with motor deterioration and atypical seizures. At the end stage of the disease, the child is in a vegetative state with decerebrate posturing. Elevated CSF protein has been reported, more so in adult phenotypes than in phenotypes affecting younger people. In nerve conduction studies, the severity of abnormalities appears to correlate with the severity of clinical symptoms.
The disease predominantly involves the white matter of the cerebral hemispheres, cerebellum, and spinal cord. Pathologic changes include a marked toxic reduction in the number of oligodendrocytes. Globoid multinucleated cells and reactive macrophages are scattered throughout the white matter. Hypomyelination may be extensive and eventually leads to white matter gliosis and scarring. Gray matter involvement in the basal ganglia region also can be found with punctate calcification.
In infantile Krabbe disease, MRI findings may be normal or show delayed myelination, but as the disease progresses, classic Krabbe features emerge. The appearance of Krabbe disease on MRI is featured as one of either two patterns. The first is a patchy hyperintense periventricular signal on T2-weighted images, consistent with hypomyelination, which eventually may become more diffuse; involvement of the thalami is often present as well. The second pattern is a patchy low signal on T2-weighted images in a similar distribution to the hyperdense regions seen on CT, which is suspected to represent a paramagnetic effect from calcium deposition in the region. Additional early changes include increased density in the distribution of the thalami, cerebellum, caudate heads, and brainstem that may precede the abnormally low attenuation of white matter in the centrum semiovale. Symmetric enlargement of the optic nerves also has been described. The distal optic nerves are primarily involved; however, a case has been described with proximal prechiasmatic enlargement of the nerves. T2 hyperintensity within the cerebellar white matter has been reported. The findings within the spinal cord are visualized as atrophic changes. Diffuse volume loss and periventricular white matter abnormalities predominate in the latter stages of this disease ( Fig. 33.3 ). Midbrain morphology on midsagittal MR images reflects the extent of neurodegeneration in Krabbe disease. The morphology of the midbrain (i.e., convex, flat, concave) appears to be a reliable tool in assessing the clinical progression of the disease. On MRI of the spine, abnormal thickening of the cauda equina roots is observed in Krabbe disease.
Proton MRS demonstrates the reduced NAA expected with neuroaxonal loss but also has revealed disturbances in glial cell metabolism associated with hypomyelination. Elevated levels of choline and mI also have been reported, which is consistent with the general neurodegenerative pattern seen on proton spectroscopy. DWI also has been applied in a limited number of patients with Krabbe disease; loss of diffusion relative anisotropy preceded changes in T2 hyperintensity.
Peroxisomes are organelles within a cell that contain enzymes responsible for critical cellular processes, including biosynthesis of membrane phospholipids, cholesterol, and bile acids; conversion of amino acids into glucose; oxidation of fatty acids; reduction of hydrogen peroxide by catalases; and prevention of excess oxalate synthesis. Peroxisomal disorders are subdivided into two major categories: (1) peroxisomal biogenesis disorders (PBDs) that arise from a failure to form viable peroxisomes, resulting in multiple metabolic abnormalities, and (2) disorders resulting from the deficiency of a single peroxisomal enzyme. Four different disorders constitute the genetically heterogeneous PBD group: Zellweger syndrome (ZS), infantile Refsum disease, neonatal adrenoleukodystrophy (ALD), and rhizomelic chondrodysplasia punctata.
ZS is an autosomal-recessive disease characterized by defective peroxisomal functions. Infants are symptomatic early, with hypotonia, seizures, hepatomegaly, and limb and facial anomalies that are easily recognizable at birth. MRI shows a diffuse lack of myelination throughout the white matter, combined with cortical dysplasia. The gyri are broad, with shallow intervening sulci found mainly in the anterior frontal and temporal lobes but also over the convexities in the perirolandic area ( e-Fig. 33.4 ). The presence of a germinolytic cyst in the caudothalamic groove is common and may have hemorrhage. In one case, signal abnormality suggestive of demyelination was identified almost solely in the brainstem corticospinal tracts. Clinical overlap may occur with other conditions, including neonatal ALD, infantile Refsum disease, and hyperpipecolic acidemia. Death usually comes with many of these conditions within the first 2 years of life.
MRS in older patients with ZS and Refsum disease reveals similar features, with dramatic lipid and choline elevations, minor mI elevations, and reduced NAA levels in sampled white matter. For rhizomelic chondrodysplasia punctata, two studies report elevations of mobile lipids, mI-glycine, and acetate and reduced choline. In contrast to ZS, infantile Refsum disease, and neonatal ALD, rhizomelic chondrodysplasia punctata does not feature liver disease, which is significant to account for the mI differences. To detect mI levels, a short echo technique (i.e., TE ≤35 msec) must be used to recognize a resonance appearing at 3.5 ppm. For MRS performed at 1.5 T, the mI resonance normally is distinct, with four of the molecule's six methine protons magnetically indistinguishable, thereby coresonating at the same location (3.5 ppm). However, increased spectral dispersion inherent at higher field strengths (3 T) produces two distinct resonances (3.5 and 3.6 ppm) for the four protons, effectively reducing the signal by half. Although some reports have found improved detection of mI at high field strength arising from increased signal/noise ratio, it may be problematic depending on the acquisition conditions.
Neonatal ALD is characterized by the presence of multiple recognizable enzyme deficiencies with grossly normal but deficient numbers of peroxisomes. Specific conditions include pipecolic and phytanic acidemia, and a deficiency of plasmalogen synthetase. This condition presents with hypotonia in the first months of life but without many of the facial features of ZS. Cortical dysplasia can be found, as well as hypomyelination, in cerebral white matter ( Fig. 33.5 ).
X-linked ALD is the prototypical peroxisomal disorder in which organelle morphology is normal on electron microscopy but a single enzyme defect, acyl-CoA synthetase, along with a failure of incorporation into cholesterol esters for myelin synthesis, leads to the accumulation of very-long-chain fatty acids and progressive CNS deterioration in the form of a chronic progressive encephalopathy. This “classic” form of ALD is an X-linked disorder with a clinical onset between the ages of 5 to 7 years, followed by a rapidly progressive decline in neurologic function and death within the ensuing 5- to 8-year period. The first indication of this condition may include mental status changes or a decline in school performance, progressing to subtle alterations in neurocognitive function, and ultimately resulting in severe spasticity and visual deficits, leading finally to a vegetative state and death. Childhood cerebral ALD, although rare, can present with raised intracranial pressure (ICP) and an elevated level of CSF protein.
CT and MRI findings in X-linked ALD show predominately posterior involvement that, over time, progresses anteriorly into the frontal lobes and from the deep white matter to the peripheral subcortical white matter. On CT, the involvement appears as symmetrical low attenuation in a butterfly distribution across the splenium of the corpus callosum, surrounded on its periphery by an enhancing zone (inflammatory intermediate zone). Three zones are readily distinguished on MR: an inner zone of astrogliosis and scarring corresponds to the low density zone seen on CT that appears hypointense on T1-weighted images and hyperintense on T2-weighted sequences; an intermediate zone of active inflammation that appears isointense on T1-weighted images and isointense or hypointense on T2-weighted images; and an outer zone of active demyelination that appears minimally hypointense on T1-weighted images and hyperintense on T2-weighted scans. Enhancement after administration of gadolinium is demonstrated within the intermediate zone of active inflammation and may disappear as the first change after bone marrow transplantation ( Fig. 33.6 ).
Proton MRS demonstrates abnormal spectra within regions of abnormal signal, as well as white matter that appears normal. The spectral profile for normal-appearing white matter of neurologically asymptomatic patients is characterized by slightly elevated concentrations of composite choline compounds, with an increase of both choline and mI reflecting the onset of demyelination. Markedly elevated concentrations of choline, mI, and glutamine in affected white matter suggest active demyelination and glial proliferation. A simultaneous reduction of the concentrations of NAA and glutamate is consistent with neuronal loss and injury. An elevated lactate level is consistent with inflammation and/or macrophage infiltration. The more severe metabolic disturbances in persons with ALD correspond to progressive demyelination, neuroaxonal loss, and gliosis leading to clinical deterioration and death. The detection of MRS abnormalities before the onset of neurologic symptoms may help in the selection of patients for bone marrow transplantation and stem cell transplantation, and monitoring after treatment. Stabilization and partial reversal of metabolic abnormalities is demonstrated in some patients.
Mitochondrial diseases generally refer to disorders of the mitochondrial respiratory chain, the only cellular metabolic pathway under control by both the mitochondrial genome (mtDNA) and the nuclear genome (nDNA). Mitochondrial diseases demonstrate impaired respiratory chain function and reduced adenosine triphosphate production. The mtDNA mutations can be divided into two categories: those that impair mitochondrial protein synthesis in toto and those that affect respiratory chain subunits. Disorders attributed to mtDNA mutations follow lax rules of mitochondrial genetics. However, disorders arising from nDNA mutations are governed by Mendelian genetics. The disorders attributed to mutations in nDNA are more abundant because most respiratory chain subunits are nucleus-encoded and the correct assembly and functioning of the entire respiratory chain require numerous steps. The clinical phenotypes of nDNA-related mitochondrial disorders tend to be uniform, whereas both the spectrum and severity of clinical manifestations associated with mtDNA-related disorders are extremely variable. Marked genotype-phenotype variability is characteristic of mtDNA-related disorders. The clinical diversity observed in patients with mtDNA-related disorders can be partially explained by heteroplasmy, the coexistence of mutant and wild-type mtDNA within a cell. Only when the proportion of mutant genomes exceeds a particular level is the disease expressed.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here